(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 18 December 2003 (18.12.2003)

PCT

(10) International Publication Number WO 03/104250 A1

(51) International Patent Classification7: C07H 19/213, A61K 31/7076

(21) International Application Number: PCT/EP03/06120

(22) International Filing Date: 10 June 2003 (10.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 02077219.0 7 June 2002 (07.06.2002) EP

(71) Applicant (for all designated States except US): KYLIX, B. V. [NL/NL]; Buntlaan 44, NL-3971 JD Driebergen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DE KONING, John [NL/NL]; Edisonstraat 135, NL-2561 BD Den Haag (NL). CHRISTENSEN, Anne [NO/NO]; Tommerasen 32, N-5232 Bergen (NO). SCHWEDE, Frank [DE/DE]; Henstedter Strasse 28, 27211 Bassum (DE). GENIESER, Hans, Gottfried [DE/DE]; Delmenhorster Strasse 18, 27809 Lemwerder (DE). DOSKELAND, Stein [NO/NO]; Nesttunhalsen 6, N-5221 Nesttun (NO). BOS, Johannes [NL/NL]; Prinses Beatrixstraat 15, NL-3981 BG Bunnik (NL).

(74) Agent: HOOIVELD, Arjen, J. W.; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: NEW COMPOUNDS FOR MODULATING THE ACTIVITY OF EXCHANGE PROTEINS DIRECTLY ACTIVATED BY CAMP (EPACS)





(57) Abstract: The present invention relates to novel compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs). In particular, the present invention relates to cAMP analogues that specifically modulate the activity of Epacs. The invention further relates to pharmaceutical compositions comprising the novel compounds, and the use of the compounds in the treatment of humans and/or animals.





